Official Guidance on MMR and Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses. The prescribing information advises against live vaccines, including MMR (measles, mumps, rubella), during treatment and for up to 4-6 weeks after the last dose due to risks of vaccine-strain infection in immunocompromised patients.[1][2]
Why Delay Live Vaccines Like MMR?
Live vaccines contain weakened viruses that replicate in the body to build immunity. Cosentyx impairs T-cell function, potentially allowing uncontrolled replication of these strains, leading to disseminated infection. Case reports with similar biologics (e.g., TNF inhibitors) show rare but serious complications like measles dissemination.[1][3] Inactivated vaccines (e.g., flu shots) are safe and recommended during treatment.[2]
Timing Recommendations
- Before starting Cosentyx: Complete MMR vaccination at least 4 weeks prior to the first dose.[1][2]
- During treatment: Do not administer live vaccines.[1]
- After stopping Cosentyx: Wait several weeks (typically 4-6) until immune function recovers before vaccinating, though exact timing varies by patient immune status—consult a doctor.[2][4]
The CDC echoes this for immunosuppressants: avoid live vaccines during therapy and shortly after.[4]
Exceptions and Special Cases
No broad exceptions exist, but:
- Fully immune adults (documented prior vaccination or positive titers) skip boosters.
- Children or high-risk groups (e.g., travel to measles outbreaks) may need risk-benefit assessment; delay non-urgent doses.
- Pregnancy: MMR is contraindicated anyway; Cosentyx data shows no fetal harm but limited use.[1][5]
Patient and Doctor Next Steps
Test immunity first via serology to avoid unnecessary delays. Discuss with a rheumatologist or immunologist for personalized timing, especially if outbreaks loom. Report any post-vaccine symptoms immediately.[2][4]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: CDC Guidelines on Immunization and Immunosuppressants
[3]: Journal of Rheumatology case reports on biologics and live vaccines
[4]: ACIP Recommendations for Biologic Users
[5]: FDA Cosentyx Label Updates